Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Screener

GHRS

GH Research PLC

May 24 • 04:00PM ET

13.70

Dollar change +0.37
Percentage change 2.78	%

Healthcare • Biotechnology • Ireland • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: EIRL ONEQ PSIL GWX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.62	Insider Own	41.49%	Shs Outstand	52.03M	Perf Week	8.73%
Market Cap	712.81M	Forward P/E	-	EPS next Y	-1.18	Insider Trans	0.00%	Shs Float	30.44M	Perf Month	30.48%
Income	-32.32M	PEG	-	EPS next Q	-0.22	Inst Own	56.31%	Short Float	4.39%	Perf Quarter	70.61%
Sales	0.00M	P/S	-	EPS this Y	-18.63%	Inst Trans	-2.83%	Short Ratio	14.26	Perf Half Y	98.26%
Book/sh	4.03	P/B	3.40	EPS next Y	-46.03%	ROA	-13.84%	Short Interest	1.34M	Perf Year	23.76%
Cash/sh	3.03	P/C	4.52	EPS next 5Y	-	ROE	-14.31%	52W Range	5.05 - 14.64	Perf YTD	136.21%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-253.12%	ROI	-15.37%	52W High	-6.42%	Beta	0.88
Dividend TTM	-	Quick Ratio	22.06	Sales past 5Y	0.00%	Gross Margin	-	52W Low	171.29%	ATR (14)	0.75
Dividend Ex-Date	-	Current Ratio	22.06	EPS Y/Y TTM	-16.88%	Oper. Margin	0.00%	RSI (14)	66.10	Volatility	7.94% 6.10%
Employees	49	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	30.40
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	29.92%	Payout	-	Rel Volume	0.40	Prev Close	13.33
Sales Surprise	-	EPS Surprise	31.82%	Sales Q/Q	-	Earnings	May 03 BMO	Avg Volume	93.70K	Price	13.70
SMA20	12.65%	SMA50	19.64%	SMA200	54.33%	Trades		Volume	37,519	Change	2.78%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-16-22	Initiated	H.C. Wainwright	Buy	$45
Jun-16-22	Initiated	ROTH Capital	Buy	$66

May-13-24 08:50AM	Recent Price Trend in GH Research (GHRS) is Your Friend, Here's Why (Zacks)
May-10-24 09:55AM	Wall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should Know (Zacks) +6.84%
May-03-24 01:53PM	GHRS Stock Earnings: GH Research Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-05-24 09:55AM	How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28% (Zacks)
07:00AM	Loading…
Feb-29-24 07:00AM	GH Research Reports Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire) +7.90%
Jan-18-24 04:30PM	GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression (GlobeNewswire)
Jan-16-24 09:55AM	Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect? (Zacks)
Dec-29-23 08:47AM	11 Best Psychedelic Stocks to Buy in 2024 (Insider Monkey)
Dec-20-23 02:15PM	11 Most Promising Psychedelic Stocks According to Hedge Funds (Insider Monkey) -7.32%
Dec-19-23 11:07AM	15 Best Falling Stocks To Buy Now (Insider Monkey) +9.13%
Nov-09-23 04:45PM	GH Research Reports Third Quarter Financial Results and Provides Business Updates (GlobeNewswire)
Sep-29-23 04:45PM	GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression (GlobeNewswire)
Aug-23-23 07:00AM	GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-17-23 11:53AM	Here's Why We're Not Too Worried About GH Research's (NASDAQ:GHRS) Cash Burn Situation (Simply Wall St.)
09:40AM	Loading…
Jul-06-23 09:40AM	Its Really a Brain Chemistry Issue: Elon Musk Embraces Ketamine in the Battle Against Depression Here Are 2 Psychedelic Stocks That Analysts Like (TipRanks)
Jun-29-23 08:00AM	The 3 Best Psychedelic Stocks to Buy Now (InvestorPlace)
May-11-23 07:30AM	GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire)
Mar-23-23 01:56PM	Down More Than 50%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks) +14.78%
Mar-12-23 12:22PM	10 Best Psychedelic Stocks to Buy According to Hedge Funds (Insider Monkey)
Mar-02-23 07:00AM	GH Research Reports Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-07-23 10:15AM	GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jan-09-23 07:30AM	GH Research Provides Business Updates and Highlights Key Upcoming Milestones (GlobeNewswire) -13.00%
Nov-21-22 12:22PM	7 Short-Squeeze Stocks for Bold Contrarians to Consider (InvestorPlace) -6.67%
Nov-10-22 07:05AM	GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +7.03%
Sep-14-22 09:55AM	Wall Street Analysts See a 262% Upside in GH Research PLC (GHRS): Can the Stock Really Move This High? (Zacks) +9.26%
Aug-30-22 03:02PM	7 Psychedelics Stocks to Buy for a Big Drug Boom (InvestorPlace) -6.01%
Aug-29-22 09:55AM	Wall Street Analysts Predict a 206% Upside in GH Research PLC (GHRS): Here's What You Should Know (Zacks) +7.95%
Aug-23-22 07:00AM	GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +5.33%
May-18-22 07:00AM	GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) -9.98%
07:04AM	Loading…
Mar-28-22 07:04AM	GH Research Reports Full Year 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-24-22 11:48AM	We're Not Very Worried About GH Research's (NASDAQ:GHRS) Cash Burn Rate (Simply Wall St.)
Dec-06-21 07:10AM	GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates (GlobeNewswire) +21.86%
07:00AM	GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression (GlobeNewswire)
Oct-27-21 04:50AM	10 Pharma Stocks to Buy According to Mark Lamperts Biotechnology Value Fund (Insider Monkey) +10.61%
Sep-25-21 10:07AM	We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business Growth (Simply Wall St.)
Sep-23-21 05:25PM	GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results (GlobeNewswire)
Jul-02-21 04:20PM	Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies (Benzinga) -5.64%
Jun-25-21 01:23PM	7 Companies Go Public Today. What Investors Need to Know. (Barrons.com)

GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients of psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schonharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

GHRS

GH Research PLC

Upgrade your FINVIZ experience